Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has recommended a Final Dividend of Rs.4/- (200%) per equity share of Rs.2/- each for the financial year ended March 31, 2026. The dividend, if approved at the forthcoming Annual General Meeting, shall be paid on or before October 24, 2026. The company has also approved the re-appointment of Dr. Sridhar Ganesan as the Managing Director for a further period of two (2) years, with effect from August 25, 2026, to August 24, 2028, subject to the approval of the Shareholders at the forthcoming Annual General Meeting.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has announced a post-results conference call invite for the quarter ended June 30, 2026, to discuss the company's financial performance.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve unaudited financial results for the quarter ended June 30, 2026, recommend final dividend for FY 2025-26, convene the 35th Annual General Meeting, and fix the record date for determining shareholder eligibility for the dividend.

Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd announced the publication of newspaper advertisements on June 22, 2026, regarding the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF). This is a routine compliance requirement as per the IEPF Authority Rules, 2016. The company is informing eligible shareholders about the process to claim their outstanding dues before the transfer.